Brazil ANVISA New Rule: GMP + AMR Reports for Feed Additives

Effective April 24, 2026, Brazil’s National Health Surveillance Agency (ANVISA) has enforced Resolution RDC No. 212/2025, mandating that all imported feed additives from China must be accompanied by both a valid Chinese GMP certificate and an antimicrobial resistance (AMR) monitoring report — specifically testing for resistance genes such as cfr and optrA — issued by a CNAS-accredited laboratory. This requirement directly affects exporters, importers, and regulatory compliance teams in the animal nutrition and veterinary supply chain.

Event Overview

On April 24, 2026, ANVISA’s RDC No. 212/2025 entered into force. Under this regulation, all feed additive imports into Brazil from China require two concurrent documents: (1) the existing Chinese GMP certification, and (2) a new AMR gene detection report validated by a laboratory accredited under China’s National Accreditation Service for Conformity Assessment (CNAS). The regulation has already caused delivery delays for some feed additive shipments from South China in April 2026. Brazilian importers are now advised to initiate document pre-review at least 90 days before anticipated customs clearance to accommodate registration timelines.

Which Subsectors Are Affected

Direct Exporters (China-based)

These companies face immediate operational impact: GMP certification alone is no longer sufficient for Brazilian market access. The added requirement for CNAS-issued AMR reports introduces new lead time, lab coordination, and documentation validation steps — particularly for products containing synthetic or semi-synthetic antimicrobial agents used in animal feed.

Importers & Distributors (Brazil-based)

Brazilian importers must now verify the validity and scope of both documents prior to shipment. Delays in obtaining compliant AMR reports have already extended registration cycles; failure to submit both documents simultaneously may result in customs hold or rejection. The 90-day pre-review recommendation reflects actual processing bottlenecks observed since implementation.

Contract Manufacturers & Blenders (China-based)

Firms supplying private-label or toll-manufactured feed additives to export clients are affected indirectly but significantly. If their production batches are not tested for specified resistance genes — and if those tests are not conducted at CNAS-accredited labs — downstream exporters cannot meet ANVISA’s dual-document requirement. This shifts quality control responsibilities upstream.

Regulatory & Compliance Service Providers

Third-party consultants and labs supporting China-to-Brazil trade must now integrate AMR gene screening into standard GMP dossier preparation. The narrow scope (cfr, optrA) and accreditation constraint (CNAS only) limit lab options and increase verification complexity — especially for multi-component formulations where gene presence may vary by raw material origin.

What Relevant Enterprises or Practitioners Should Focus On and How to Respond

Monitor official updates on scope clarification

ANVISA has not yet published a public list of feed additive categories explicitly subject to the AMR reporting requirement. Analysis来看, the current enforcement appears focused on additives with known antimicrobial activity (e.g., pleuromutilins, oxazolidinones), but regulatory interpretation may expand. Stakeholders should track ANVISA’s upcoming Q&A guidance or technical notes.

Verify CNAS lab capability for targeted gene detection

Not all CNAS-accredited labs offer cfr/optrA detection using ISO/IEC 17025-compliant methods. From industry angle, exporters should confirm test methodology (e.g., qPCR vs. whole-genome sequencing), detection limits, and report formatting compatibility with ANVISA’s digital submission portal — before initiating sampling.

Distinguish between policy signal and operational reality

The 90-day pre-review window is a pragmatic response to observed delays, not a formal ANVISA deadline. Current more suitable understanding is that this reflects real-world processing constraints rather than a codified timeline. Companies should treat it as a de facto minimum buffer, not a guaranteed approval window.

Align internal QA/QC protocols with export destination requirements

For manufacturers producing for multiple markets, this rule highlights growing divergence in regulatory expectations. Analysis来看, integrating AMR gene screening into routine batch release — at least for Brazil-bound lots — reduces last-minute bottlenecks. It also supports traceability in case of future audits or market recalls linked to resistance concerns.

Editor Perspective / Industry Observation

This regulation is better understood as an early-stage signal of tightening global scrutiny on antimicrobial use in animal production — not merely a procedural update. Observation来看, ANVISA’s pairing of GMP compliance with AMR surveillance reflects a broader shift toward risk-informed regulation, where manufacturing quality is assessed alongside biological impact potential. From industry angle, it signals increasing convergence between food safety, veterinary public health, and One Health frameworks in emerging-market regulatory design. Continued attention is warranted because similar requirements may emerge in other Mercosur members or WHO-aligned jurisdictions seeking harmonized AMR mitigation strategies.

Conclusion

ANVISA’s RDC No. 212/2025 does not represent a standalone compliance hurdle, but rather a marker of evolving regulatory priorities at the intersection of feed safety and antimicrobial stewardship. It is neither a temporary administrative change nor a fully matured framework — instead, it is an active, early-phase development requiring adaptive responsiveness. Current more appropriate interpretation is that this is a threshold-level requirement, one that tests readiness across documentation, lab capacity, and cross-border coordination — and sets precedent for how AMR-related data may increasingly anchor market access decisions in regulated agricultural inputs.

Information Sources

• Brazilian National Health Surveillance Agency (ANVISA) – RDC No. 212/2025 (official text, effective April 24, 2026)
• Public notices issued by ANVISA’s Coordination of Veterinary Products (CGPV) regarding implementation timelines and document acceptance criteria
• Verified field reports from South China-based feed additive exporters (April 2026 shipment delays, anonymized)
• Observation of 90-day pre-review guidance communicated directly by Brazilian importers to Chinese suppliers — subject to ongoing verification as ANVISA’s operational guidance evolves